Breast Cancer Foundation NZ
MK-2870-011/TroFuse-011
Advanced Breast Cancer clinical trials for Triple negative
Researchers want to know if MK-2870 given by itself or with Keytruda (pembrolizumab) can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with MK-2870 alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
This is a phase 3, randomized, open-label study comparing the efficacy and safety of MK-2870, given alone or in combination with Keytruda (pembrolizumab) versus treatment of physician's choice in patients with previously untreated locally recurrent (unable to be surgically removed) or metastatic triple-negative breast cancer expressing PD-L1 at CPS Less Than 10.
The drug, MK-2870, is also known as sacituzumab tirumotecan.
Criteria:
- Patients aged 18 years or over
- Previously untreated locally recurrent (unable to be surgically removed) or metastatic triple-negative breast cancer
- PD-L1 at CPS < 10.
Information about this trial can also be found on the website of Harbour Cancer and Wellness.
A qualified healthcare professional will help you to determine if you are eligible to take part in this clinical trial. This information may be useful in starting a conversation with your doctor.
New Zealand
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.